A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
Price : $35 *
At a glance
- Drugs Amiselimod (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 06 Dec 2016 Results assessing cardiac safety profile published in the British Journal of Clinical Pharmacology (2016).
- 19 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.